Cleveland Biolabs, Inc. Logo Image

Cleveland Biolabs, Inc.

Most Recent Annual Report

2015 Annual Report and Form 10K

Cleveland Biolabs, Inc.

Cleveland Biolabs, Inc. does not currently have any hardcopy reports available on AnnualReports.com. Click the button below to be notified when hardcopies become available.



Archived Annual Reports

About Cleveland Biolabs, Inc.

51-200 Employees
Based in Buffalo, New York

Cleveland BioLabs, Inc. is a biotechnology focused on developing biodefense, tissue protection and cancer treatment drugs based on concept of modulation of cell death for therapeutic benefit. CBLI's pipeline includes products from two primary families of compounds: protectans and curaxins. It is developing protectans as drug candidates that protect healthy tissues from acute stresses, such as , chemotherapy and ischemia. Curaxins are being developed as anticancer agents that could act as mono-therapy drugs or in combination with other existing anticancer therapies.

Ticker:
CBLI
Exchange:
NASDAQ (See More NASDAQ Companies)
Industry:
Research Services (See More Research Services Companies)
Sector:
Services (See More Services Companies)

Looking for Other Annual Reports?

Search by company name or ticker symbol